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Intradialytic hypotension is a most frequent complication of
hemodialysis and may contribute to cardiovascular events
and high mortality. There is a hypothesis that an increase in
adenosine generation during hemodialysis may cause
vasodilation and a decrease in cardiac output, which results
in systemic hypotension. We studied whether this can be
blocked by an adenosine A1 receptor antagonist. We
investigated the effects of an A1 antagonist, FK352, injection
in 30 chronic hemodialysis patients with frequent
intradialytic hypotension by a prospective, multicenter,
double-blind placebo-controlled study for 4 weeks after
4 weeks of the observation period. Intradialytic hypotension
was defined as systolic blood pressure (SBP) less than
110 mmHg, with SBP drop of more than 30 mmHg from the
predialysis level. The efficacy of FK352 was primarily assessed
by the reduction rate of dialysis hypotension between the
FK352 and placebo groups. Incidence of emergency
treatments caused by hypotension was evaluated. FK352
(50 mg, intravenous) or an equivalent placebo was injected
into the dialysis circuit 1 h after starting dialysis. Blood
pressure and heart rate were monitored every 30 min
during dialysis. FK352 significantly improved intradialytic
hypotension (P¼ 0.046), in that the reduction rates of
intradialytic hypotension in the FK352 and placebo groups
were 12.8% (Q1 (first quantile), Q3 (third quantile): 27.5,
1.7), and þ 8.3% (Q1, Q3: 16.6, þ 16.7), respectively.
The frequency of discontinuation of dialysis was significantly
reduced by FK352. No apparent side effects were observed
from treatment with FK352. In conclusion, the A1 antagonist
FK352 may offer a novel therapeutic option for chronic
dialysis patients associated with intradialytic hypotension.
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End-stage renal disease (ESRD) patients are continuously
increasing and the total number of hemodialysis patients is
estimated to be over 1 650 000 in the world.1 In Japan, the
number of ESRD patients in 2004 exceeded 240 000, and the
patients receiving long-term hemodialysis has considerably
increased. More than 15 000 hemodialysis patients have been
undergoing hemodialysis therapy for more than 20 years.
Long-term dialysis therapy causes various complications
including intradialytic hypotension.
There are two types of dialysis hypotension: intradialytic
hypotension and chronic persistent hypotension. Up to 33%
of hemodialysis patients are suffering from intradialytic
hypotension, which requires an action to resume blood
pressure during hemodialysis,2,3 and the incidence of intra-
dialytic hypotension is expected to increase in accordance
with the increase of the elderly, diabetic patients, and patients
with cardiovascular diseases.4 Intradialytic hypotension often
engenders hemodialysis interruption and may be responsible
for a reluctance in patients to extend their dialysis treatment
time, eventually leading to increased morbidity and mortality
by brain ischemia and cardiovascular diseases.5,6
Several factors contribute to intradialytic hypotension. These
include rapid fluid removal, rapid reduction in plasma
osmolality, autonomic dysfunction, limited cardiac reserve,
and increased synthesis of endogenous vasodilators.7,8 The
gradual blood pressure reduction results from an intravascular
hypovolemic condition due to hemodialysis. In contrast, sudden
and profound hypotension from diminished cardiac output and
vasodilation has been theorized. Krepel et al.9,10 reported that
the level of relative blood volume was not correlated with blood
pressure and the level of relative blood volume reduction at
which hypotension occurred was highly variable. The accumu-
lation of the locally released adenosine may play a central role in
sudden intradialytic hypotension. The proposed hypothesis is
that a vicious cycle may occur in patients with sudden
hypotension: hypotension induces ischemia, which, in turn,
increases local adenosine release, which then causes inhibition of
norepinephrine release and eventually causes vasodilation, thus
resulting in deepening hypotension.11,12 In fact, concentrations
of adenosine and its metabolite, inosine, and hypoxanthine, are
reported to increase after hemodialysis.11,12
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Adenosine exerts its physiological actions to stimulate
adenosine receptors (A1, A2a, A2b, and A3) on the cell
membrane.13 Functions of A1 and A2a receptors have been
well studied. Adenosine A1 receptor stimulation results in
suppression of cardiac contractility, heart rate reduction,
suppression of catecholamine release from sympathetic nerve
endings, and renin release. FK352, an adenosine receptor A1
antagonist, exhibits high affinity and high selectivity for the
human adenosine A1 receptor. Although the central nervous
system abounds in adenosine A1 receptors,14 FK352 has little
effect on the central nervous system. One of the reasons is
thought to be that the character of hydrophilicity of FK352
does not allow it to be distributed into the central nervous
system (data not shown).
To prove the hypothesis that dialysis hypotension is caused
by ischemia-induced adenosine generation, we investigated
the effects of FK352 infusion on dialysis hypotension by a
multicenter, randomized, double-blind, placebo-controlled,
intergroup comparative study.
RESULTS
Effects of FK352 treatment on the incidence of intradialytic
hypotension
FK352 significantly improved intradialytic hypotension
(P¼ 0.046), in that the reduction rates of dialysis hypo-
tension in the FK352 and placebo groups were 12.8%
(Q1 (first quantile), Q3 (third quantile): 27.5, 1.7), and
þ 8.3% (Q1, Q3: 16.6, þ 16.7), respectively (Figure 1b).
Intradialytic hypotension was significantly suppressed in the
FK352 group (P¼ 0.010), whereas it was not changed in the
placebo group (P¼ 0.637) (Figure 1a).
As the two variables of frequency of intradialytic hypo-
tension and duration of hemodialysis exhibited imbalance
(Po0.15), the incidence of intradialytic hypotension during
the observation period was adjusted. After adjustment,
FK352 significantly suppressed intradialytic hypotension
also (P¼ 0.030).
To further analyze the efficacy of FK352 on intradialytic
hypotension, we compared the FK352 and placebo groups
after omitting the dialysis sessions in which body fluid was
removed at the excessive ultrafiltration rate of more than
0.3 ml/kg/min. Three patients in the FK352 group were
omitted because they were frequently treated with the
excessive ultrafiltration rate. On the other hand, no patient
in the placebo group was removed from the data for analysis.
The reduction rates of dialysis hypotension in the FK352 and
placebo groups were 12.8% (Q1, Q3: 30.0, 8.3) and
þ 8.3% (Q1, Q3: 16.6, þ 16.7), respectively (Figure 2),
suggesting that FK352 significantly improved intradialytic
hypotension (P¼ 0.049).
As shown in Figures 3 and 4, the intradialytic hypotension
of the hemodialysis patients was significantly suppressed by
FK352 and the efficacy was more prominent in proportion to
the degree of drop in blood pressure. With the intradialytic
hypotension defined at systolic blood pressure (SBP) less
than 100 mmHg, the reduction rates of dialysis hypotension
in the FK352 and placebo groups were 16.7% (Q1, Q3:
34.5, þ 0.8) and þ 8.3% (Q1, Q3: 16.7, þ 25.0),
respectively (Figure 3), suggesting that FK352 significantly
improved intradialytic hypotension (P¼ 0.018). With intra-
dialytic hypotension defined as SBP less than 90 mmHg, the
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Figure 1 | Effects of administration of FK352 or placebo on
intradialytic hypotension. (a) Change in the incidence of intradia-
lytic hypotension in each patient. FK352, n¼ 16; placebo, n¼ 14.
Data show median and Q1–Q3. (b) Reduction rate of intradialytic
hypotension. Data are expressed as median and Q1–Q3.
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Figure 2 | Effects of administration of FK352 or placebo on
intradialytic hypotension (SBP drop below 110 mmHg) after
omitting the cases with excess ultrafiltration. (a) Change in the
incidence of intradialytic hypotension in each patient. FK352, n¼ 13;
placebo, n¼ 14. Data show median and Q1–Q3. (b) Reduction rate of
intradialytic hypotension. Data are expressed as median and Q1–Q3.
100
90
80
70
60
50
40
30
20
10
0
Observation
period
Medication
period
Observation
period
Medication
period
(%)
100
90
80
70
60
50
40
30
20
10
0
(%)
20
25
15
10
5
0
–5
–10
–15
–20
–25
–30
–35
(%)
FK352 Placebo
P = 0.018
FK352 Placebo
a b
Figure 3 | Effects of administration of FK352 or placebo on
intradialytic hypotension (SBP drop below 100 mmHg) after
omitting the cases with excess ultrafiltration. (a) Change in the
incidence of intradialytic hypotension in each patient. FK352, n¼ 13;
placebo, n¼ 14. Data show median and Q1–Q3. (b) Reduction rate of
intradialytic hypotension. Data are expressed as median and Q1–Q3.
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reduction rates of dialysis hypotension in the FK352 and
placebo groups were 12.5% (Q1, Q3: 16.7, 0.0) and
þ 2.8% (Q1, Q3: 0.0, þ 27.3), respectively (Figure 4),
suggesting that FK352 significantly improved intradialytic
hypotension (P¼ 0.032). FK352 prominently improved
intradialytic hypotension, particularly in severer cases.
Effect of FK352 on events with emergent treatment during
hemodialysis
The incidence of dialysis sessions with emergency treatments
is shown in Table 1. The incidence of infusion was not
different between the FK352 and placebo groups during the
observation period (Table 1). However, discontinuation of
dialysis was significantly suppressed by FK352 treatment
(Table 1 and Figure 5). The major problem of intradialytic
hypotension is discontinued dialysis, which often causes
overhydration and underdialysis of the patients. In the
placebo group, only one of eight showed an improved
change, whereas all the subjects in the FK352 group (Figure 5)
had reductions in the frequency of discontinuation or
suspension of fluid removal.
Pharmacokinetics of FK352 in dialysis patients
Plasma concentration of FK352 in hemodialysis patients was
initially at 10 mg/ml and gradually decreased to 1 mg/ml, 2 h
after the injection (Figure 6). The plasma concentrations of
FK352 of hemodialysis patients were similar to those of
healthy volunteers.
No apparent side effects were observed with use of FK352
for dialysis hypotension.
DISCUSSION
It is critically important to keep an adequate dialysis dose and
sufficient dialysis time for improving the prognosis of dialysis
patients. Intradialytic hypotension is a major problem in
maintaining adequate dialysis because it compels a limit to
dialysis time and dialysis condition. In the present study,
FK352 improved intradialytic hypotension significantly in
chronic hemodialysis patients, who were intradialytic hypo-
tension prone. Although the incidence of saline infusion for
intradialytic hypotension was not significantly different with
FK352 administration, the incidence of discontinuation of
hemodialysis was significantly decreased, indicating that
FK352 improves intradialytic hypotension, particularly in
severer cases.
Intradialytic hypotension occurs as a result of intra-
vascular hypovolemia and impaired cardiovascular reactivity
to the decrease of intravascular volume. When the dry weight
Observation
period
Medication
period
Observation
period
Medication
period
100
90
80
70
60
50
40
30
20
10
0
(%)
100
90
80
70
60
50
40
30
20
10
0
(%)
20
25
30
15
10
5
0
–5
–10
–15
–20
(%)
FK352 Placebo
P = 0.032
FK352 Placebo
a b
Figure 4 | Effects of administration of FK352 or placebo on
intradialytic hypotension (SBP drop below 90 mmHg) after
omitting the cases with excess ultrafiltration. (a) Change in the
incidence of intradialytic hypotension in each patient. FK352, n¼ 13;
placebo, n¼ 14. Data show median and Q1–Q3. (b) Reduction rate of
intradialytic hypotension. Data are expressed as median and Q1–Q3.
Table 1 | Event with the emergent treatments for blood pressure reduction incidence of dialysis sessions with event (%)
FK352 group (n=16) Placebo group (n=14)
Treatments Observation period Dosing period Observation period Dosing period
FK352 group vs
placebo groupa
Infusion 28.7% (16.7–58.4) 27.5% (8.3–47.8) 25.0% (16.7–75.0) 26.7% (16.7–83.3) P=0.226
P=0.197b P=0.951b
Discontinuation of hemodialysis 0.0% (0.0–4.2) 0.0% (0.0–0.0) 0.0% (0.0–8.3) 4.2% (0.0–10.0) P=0.003
P=0.125b p=0.063b
Reduction or suspension of ultrafiltration 0.0% (0.0–8.3) 0.0% (0.0–8.3) 0.0% (0.0–8.3) 0.0% (0.0–9.1) P=0.436
P=0.406b P=0.211b
Othersc 0.0% (0.0–16.7) 0.0% (0.0–8.3) 0.0% (0.0–8.3) 0.0% (0.0–8.3) P=0.609
p=0.922b p=0.344b
Data are expressed as median (Q1–Q3).
aMann–Whitney U-test for the group comparison of difference between dosing period and observation period.
bWilcoxon signed rank test for the intragroup comparison of difference between dosing period and observation period.
cBody positional changes, reduction of blood flow rate, lowering dialysate temperature, O2 inhalation, and so on.
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Figure 5 | Effects of administration of FK352 or placebo on
discontinuation of dialysis for intradialytic hypotension.
(a) Change in the incidence of discontinuation of dialysis in each
patient. FK352, n¼ 16; placebo, n¼ 14. Data show median and
Q1–Q3. (b) Reduction rate of discontinuation of dialysis. Data are
expressed as median and Q1–Q3.
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is optimal, the ultrafiltration rate is the main determinant of
intravascular volume. The excess removal of extracellular
volume, when the ultrafiltration rate is beyond 0.3 ml/kg/
min, frequently results in intradialytic hypotension. If the
dialysis sessions with excess ultrafiltration beyond 0.3 ml/kg/
min are removed, the impact of FK352 on intradialytic
hypotension becomes more prominent, as shown in Figures
2–4. Most cases of intradialytic hypotension seem to happen
by impaired cardiovascular reactivity. The mechanism for the
impaired reactivity of the cardiovascular system is largely
obscure although several hypotheses have been proposed:
autonomic dysfunction, generation of adenosine and so on.
It has been proven that the increase in adenosine, which is
generated from ischemic tissue by ATP degradation, reduces
vessel tone and lowers blood pressure. A high concentration
of adenosine and its metabolites has been reported after
ischemic events. Woolliscroft and Fox15 demonstrated that
the increase in urine oxypurine/creatinine ratio was observed
after hypotensive events of 19 patients who were associated
with chronic heart failure, liver diseases and so on. In
hemodialysis patients under acetate dialysis, dialysis hypo-
tension was often seen and plasma inosine, hypoxanthine,
xanthine, and uric acid were increased after dialysis.16
According to their data, the increase in ATP metabolites
was prominent in acetate dialysis within 1 h after dialysis,
which was often associated with dialysis hypotension,
whereas bicarbonate dialysis was not often associated with
a significant increase in ATP metabolites, although a mild
peak was seen at 2 h after dialysis. The most relevant report
was published by Shinzato et al.11 They measured inosine,
hypoxanthine and xanthine at the time of sudden hypo-
tension and showed a significant increase in these adenosine
metabolites at the time of hypotension. Guieu et al.12 also
measured serum adenosine and inosine concentrations in
dialysis patients and showed that the serum adenosine
concentrations were increased more than twice as much as
the controls before and after dialysis.
A1 receptor inhibition was attempted by administration of
caffeine in patients with hemodialytic hypotension. Shinzato
et al.11 showed that administration of caffeine attenuated
dialysis hypotension significantly. These results suggest that
adenosine may play a major role in dialysis hypotension.
However, caffeine is not a selective A1 antagonist and
increases blood pressure and heart rates in most cases. In
contrast, FK352 is a selective A1 antagonist and does not
affect cardiovascular function and locomotor activity in the
brain.
What is the mechanism for prevention of dialysis
hypotension by FK352? The A1 receptors, which are reported
to be distributed in the ends of sympathetic nerves, suppress
the release of catecholamines from the ends of the nerves.17
Adenosine selectively inhibits contractions of the rabbit
portal vein evoked by adrenergic nerve stimulation via
activation of an A1 receptor.18 This means that adenosine
could inhibit constriction of peripheral vessels via the A1
receptors in the ends of the nerves. FK352 may restore the
adenosine-induced decline in constriction. It is known that
adenosine decreases cardiac function and expands coronary
arteries to protect the organ from ischemia-induced damage.
The cardiac action of adenosine is depression of sinoarterial
and arterioventricular node activity, leading to a reduced
heart rate. However, heart rate was not changed significantly
in the present study. We might have missed the reduction in
heart rate because we did not continuously monitor heart
rate and blood pressure. In dialysis patients, the increase in
adenosine concentration in peripheral tissue presumably
precedes the increase in adenosine in systemic circulation, as
peripheral tissue ischemia occurs in advance of systemic
hypotension. Alternatively, the A1 antagonist may directly
affect autonomic regulation. This possibility needs to be
studied. The A1 receptor does not involve dilation of
coronary arteries. These arteries express adenosine A2
receptors, which mediate vasodilation.19 Therefore, FK352
does not inhibit these protective actions of adenosine. This
has been reported as a beneficial role of antagonism of the
cardiodepressant effects of adenosine.19,20 The cardiodepres-
sant actions of adenosine may protect our bodies against
hemorrhage or angina. However, it is plausible that the
depressant effect of adenosine induces sudden hypotension,
which in turn causes serious injuries to the brain and heart.
FK352 does inhibit the excessive suppressive action of
adenosine on cardiac function.
In our study, the frequency of dialysis hypotension was
attenuated by FK352, but not totally eliminated. This result
may imply that the administration of FK352 might have been
insufficient to prevent the intradialytic hypotension in some
cases. The adequate treatment dose of FK352 and injection
time to completely prevent dialysis hypotension need to be
determined by further studies. Alternatively, the cause of
hemodialytic hypotension is variable and A1 inhibition is not
enough to prevent dialysis hypotension.
In this study, intradialytic hypotension tended to happen
more frequently in control subjects during the dosing period
compared to the observation period. The reason is obscure,
but we speculated that the patients were stressed about
obeying the protocol because the dialysis condition was not
to be changed for 8 weeks. Such a tense condition might
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Figure 6 | Pharmacokinetics of FK352. Plasma FK352 concentra-
tion in healthy subjects (—) and dialyzed patients (----).
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reduce the frequency of intradialytic hypotension during the
first 4 weeks of the observation period. The dialysis
conditions, in particular dry weight, are usually made
through fine adjustment to retain the patients’ physical
condition appropriately. There was a possibility that the real
dry weight might be changed in the last 4 weeks, although the
cardiothoracic ratio and the size of inferior vena cava were
not changed. Nevertheless, the incidence of intradialytic
hypotension was significantly reduced with FK352, suggest-
ing that FK352 may be effective even under adverse
conditions and we may be underestimating the action.
In conclusion, FK352 was clinically useful for improve-
ment of intradialytic hypotension in this small clinical trial,
particularly in severe cases, which may improve the prognosis
of hemodialysis patients. The outcome of this study suggests
that intradialytic hypotension is, at least in part, caused by
generation of adenosine during hemodialysis in peripheral
tissue. In addition, FK352 significantly reduces the frequency
of emergency treatment during dialysis therapy, which may
decrease the practical labor of the dialysis staff. The favorable
impact of FK352 needs to be confirmed in a large-scale
clinical trial by enrolling severer cases.
MATERIALS AND METHODS
Study subjects
Chronic hemodialytic patients who were suffering from frequent
intradialytic hypotension lasting 6 months were recruited from
hospitals and outpatient clinics in the Osaka area between January
of 2002 and January of 2003. The inclusion criteria were outpatients
on chronic hemodialysis three times a week in a supine position,
whose predialytic SBP is 120 mmHg or more, and who have four or
more dialysis sessions with intradialytic hypotensive episode(s) out
of 12 hemodialysis sessions in 4 weeks. Ages range from over 20 to
less than 75 years of age. The exclusion criteria were as follows:
patients with serious hemodialysis-induced hypotension, by which it
means that hemodialysis could not be completed without a pressure
agent. Patients with any of the following complications were
excluded: serious hypertension (SBP 200 mmHg or more and
diastolic blood pressure 110 mmHg or more), serious hemorrhage
disease (cerebral hemorrhage and ulcer accompanied by hemo-
rrhage), serious cardiovascular diseases (myocardial infarction that
occurred in the past 6 months, severe heart failure), and liver
diseases, diabetic retinopathy in pre-proliferative stage or prolif-
erative stage (although cases with stabilized bleeding by photo-
coagulation were enrolled), severe anemia requiring blood
transfusion and having just started erythropoietin therapy.
Informed consent was obtained from 53 patients. Twenty
patients were withdrawn from the clinical trial for the following
reasons: seven patients did not meet the criteria of dialysis
hypotension; five patients voluntarily withdrew; five patients needed
to have their dry weight changed; one was admitted to a hospital;
one had trouble with a shunt; one could not have his/her dialysis
condition adjusted. Three patients were omitted from the data for
analysis because the number of dialysis treatments for statistical
analysis on these patients was insufficient.
The Investigational Product Allocation Director independently
decided the eligibility of subjects under inclusion criteria and
exclusion criteria and allocated them to FK352 and placebo groups
at a 1:1 ratio. An observation period of 4 weeks was established
before the initial administration of the investigational product, and
the Investigational Product Allocation Director judged when to
progress to the dosing period.
Fourteen subjects (10 men, four women) were assigned to the
placebo group and 16 subjects (11 men, five women) were assigned
to the FK352 group. Patient profiles at the entry of this study are
shown in Table 2. The subjects provided written, informed consent
for the study and approval was obtained from both the Osaka
Prefecture Medical Association research ethics committee and the
individual hospital review boards. The study was carried out in
accordance with the Declaration of Helsinki.
FK352
FK352((E,R)-[1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-
piperidin-2-yl] acetic acid), which is an adenosine receptor A1
antagonist developed by Fujisawa Pharmaceutical Co., Ltd, exhibits
high affinity and high selectivity for human adenosine receptor A1.
Study protocol
The study was performed in a randomized, double-blind, placebo-
controlled and comparative manner. All subjects were adjusted to a
hemodialysis condition for 2 weeks followed by the observation
period for 4 weeks, and finally the subjects were treated with FK352
or placebo administration for 4 weeks. During the dosing period,
50 mg of FK352 or placebo was administrated 1 h after hemodialysis,
as the elimination half-life of FK352 is 3 h.
The hemodialysis adjusted condition period was set to ensure
constant hemodialysis conditions during the observation period
(4 weeks) and the medication period (4 weeks), totaling 8 weeks.
During this period, all hemodialytic conditions had to be set,
including dry weight, 4 h of hemodialysis, days of the week with
hemodialysis, scheduled hemodialysis hours of the day, blood flow
volume, dialysis solution type (bicarbonate dialysis solution),
dialysis solution flow volume, dialysis solution temperature, anti-
coagulant type, dialyzer type, (membrane type), meal timing, and
timing of body positional changes (e.g. lifting legs and so on).
Periodic body position changes were permitted only as a routine
action to prevent dialysis hypotension prophylactically. Feasibility of
hemodialysis under the above conditions during the observation
period and the dosing period for a total of 8 weeks was confirmed.
Hemodialysis was performed with bicarbonate dialysate. The
dialysate sodium concentration was 140–142 mEq/l, dialysate
potassium 2 mEq/l and dialysate calcium 2.5 or 3.0 mEq/l. The
duration of dialysis sessions was set to be 4 h except when infusion
therapy was performed. Ultrafiltration rate was set to be constant
over the course of a dialysis session. The postdialytic body weight
has been governed to achieve dry weight not in every dialysis
session, but at least once a week.
Blood pressure was measured every 30 min. To treat the
symptoms associated with intradialytic fall of blood pressure or to
prevent the further reduction of blood pressure, saline infusion was
performed at first. As a rule, when SBP is less than 140 mmHg, with
20 mmHg or more reduction compared to SBP 1 h before, 100 ml
(one unit) saline infusion or injection of 20 ml (one unit) of 10%
NaCl is permitted.
Emergency actions other than infusion therapy were based on
specific criteria. If the infusion therapy was unsuccessful, positional
change (lifting the legs), reduction of ultrafiltration rate, oxygen
inhalation, discontinuation of hemodialysis, and shortening of
dialysis were conducted.
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Evaluation of the efficacy of FK352 on dialysis hypotension
The primary assessment of FK352 efficacy was the reduction rate in
the incidence of intradialytic hypotension between the placebo and
the FK352 groups. Intradialytic hypotension is defined as SBP
decreasing to less than 110 mmHg, with 30 mmHg or more
reduction of blood pressure from the predialysis level.
An event is defined as emergency treatments against blood
pressure reduction: infusion of saline or 10% NaCl, reduction of
ultrafiltration, oxygen inhalation and discontinuation of hemo-
dialysis or shortening of dialysis time. Incidence of hemodialysis
sessions with intradialytic hypotension(s) and event(s) was evalu-
ated.
In cases of excessive body weight increase due to too much food
and fluid intake, however, the dialysis sessions inevitably set at an
ultrafiltration rate of more than 0.3 ml/kg/min often have problems.
The data were excluded from statistical analysis when patients
underwent an excessive ultrafiltration rate of 0.3 ml/kg/min or more.
After the exclusion of dialysis sessions with excess ultrafiltration,
three patients who had less than six dialysis sessions for the data
analysis were excluded.
To further analyze the efficacy of FK352 on severe intradialytic
hypotension, intradialytic hypotension was defined as SBP decreas-
ing to less than 110, 100, and 90 mmHg.
Pharmacokinetic measurement of FK352
Whole blood concentration of FK352 was analyzed before admin-
istration and at 3, 10, and 30 min and 1 and 2 h after administration
of FK352 during hemodialysis. FK352 concentration was measured
by liquid chromatography and mass spectrometry. Estimated plasma
concentration of FK352 (C0) was calculated from the concentrations
at 3 and 10 min after administration. Pharmacokinetics of normal
subjects was measured in 10 healthy volunteers after informed
consent was obtained from them.
Statistical analysis
For demographic and other baseline variables, Fisher’s exact test,
t-test or Mann–Whitney U-test were used to assess comparability
between the FK352 and placebo groups. Variables that exhibited
imbalance (Po0.15) between treatment groups were to be included
as a covariate in secondary analysis (rank analysis of covariance) to
assess the effect of the imbalance. Mann–Whitney U-test was used
for group comparison (comparison between the placebo and FK352
groups) and Wilcoxon signed rank test was used for intragroup
comparison (comparison between the observation and medication
periods). Statistical significance level was defined as Po0.05.
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